当前位置：首页 > 文献互助 > 互助详情

… therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor复制

用户b8hUGnyUFz-o 14天前 43 10 已关闭

DOI:复制

文献链接:复制

其他信息:

L Wang, M Xiong, X Gao, C Zhou, Y Han, Y Li…
Cancer …, 2024
aacrjournals.org
… -payload ADC with high homogeneity and quality. For HER3 dpADC, HER3 Ab was conjugated with a novel Topoisomerase I inhibitor, TopoIx, and an EGFR tyrosine kinase inhibitor. In …

上一篇：Efficacy of Modified Peanut Skin Decoction for Lung Cancer Myelosuppression

下一篇：The adverse effects of oral niacin/nicotinamide - an overview of reviews

互助时间线

2025-11-17 16:42:15 [关闭求助]

系统关闭了求助

备注: 显示free已经是全文了 没有下载选项 直接看网页哦

2025-11-17 14:51:54 [发起求助]

最新发布的求助

Index Structures for Biological Sequences 3小时前
Drugging the efferocytosis process: concepts and opportunities. 4小时前
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model 5小时前
Comprehensive 3d Transition Metal Single‐Atom Modulation Tunes Ni‐MOF D‐Band for Alkaline OER 6小时前
Decoupling of nitrogen, phosphorus, and carbon release from fine and coarse roots during 7 years of decomposition 6小时前
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure 6小时前
Tetrahedral Framework Nucleic Acid-Based Delivery of miR-34a Inhibitor for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. 7小时前
A practical guide to large-scale docking 7小时前
Bicyclo[1.1.1]pentane-Derived Building Blocks for Click Chemistry 7小时前
Expanding Therapeutic Horizons in Parkinson's Disease Through MicroRNA-Based Interventions: A Comprehensive Review 8小时前
{Formulated Preparations- Specific Monographs} Rivastigmine Capsules - british pharmacopoeia[1731412457.779041.html] 9小时前
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China 10小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com